Homocysteine lowering interventions for peripheral arterial disease and bypass grafts

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 7, 2013, Pages

  Andras, Alina ^a   Stansby, Gerard ^b   Hansrani, Monica ^c  

^a FREEMAN HOSPITAL   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c JAMES COOK UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5 METHYLTETRAHYDROFOLIC ACID; FOLIC ACID; HOMOCYSTEINE; PLACEBO; VITAMIN B GROUP; 5-METHYLTETRAHYDROFOLATE; TETRAHYDROFOLIC ACID DERIVATIVE; VITAMIN B COMPLEX;

AMINO ACID BLOOD LEVEL; ANKLE BRACHIAL INDEX; BIBLIOGRAPHIC DATABASE; BYPASS SURGERY; CLINICAL OUTCOME; DISEASE COURSE; HUMAN; HYPERHOMOCYSTEINEMIA; LIMB AMPUTATION; MORTALITY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGISTER; REVIEW; SYSTEMATIC REVIEW; TREATMENT RESPONSE; ARTERIOSCLEROSIS; BLOOD; BLOOD VESSEL GRAFT; COMPLICATION; PERIPHERAL VASCULAR DISEASES; PERIPHERAL VASCULAR DISEASE;

ARTERIOSCLEROSIS; DISEASE PROGRESSION; FOLIC ACID; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; PERIPHERAL VASCULAR DISEASES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TETRAHYDROFOLATES; VASCULAR GRAFTING; VITAMIN B COMPLEX;

EID: 84891657429     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD003285.pub2     Document Type: Review

References (69)

1. Khandanpour N, Armon MP, Jennings B, Finglas PM, Willis G, Clark A, et al. Randomized clinical trial of folate supplementation in patients with peripheral arterial disease. British Journal of Surgery 2009;96(9):990-8.
2. Khandanpour N, Armon MP, Jennings B, Willis G, Clark A, Meyer FJ. Folate supplementation improves arterial function in patients with peripheral arterial disease: a randomised double-blind, placebo-controlled clinical trial. The Vascular Society of Great Britain & Ireland Yearbook 2008. 2008:81.
3. Sydow K, Schwedhelm E, Arakawa N, Bode-Böger SM, Tsikas D, Hornig B, et al. ADMA and oxidative stress are responsible for endothelial dysfunction in hyperhomocyst(e)inemia: effects of L-arginine and B vitamins. Cardiovascular Research 2003;57(1):244-52.
4. Carrero JJ, López-Huertas E, Salmerón LM, Baró L, Ros E. Daily supplementation with (n-3) PUFAs, oleic acid, folic acid, and vitamins B-6 and E increases pain-free walking distance and improves risk factors in men with peripheral vascular disease. The Journal of Nutrition 2005;135(6):1393-9.
5. Constans J, Blann AD, Resplandy F, Parrot F, Renard M, Seigneur M, et al. Three months supplementation of hyperhomocysteinaemic patients with folic acid and vitamin B6 improves biological markers of endothelial dysfunction. British Journal of Haematology 1999;107(4):776-8.
6. De Jong SC, Stehouwer CD, van den Berg M, Geurts TW, Bouter LM, Rauwerda JA. Normohomocysteinaemia and vitamin-treated hyperhomocysteinaemia are associated with similar risks of cardiovascular events in patients with premature peripheral arterial occlusive disease. A prospective cohort study. Journal of Internal Medicine 1999;246(1):87-96.
7. Garg R, Malinow M, Pettinger M, Upson B, Hunninghake D. Niacin treatment increases plasma homocyst(e)ine levels. American Heart Journal 1999;138(6 Part 1):1082-7.
8. Lonn E, Yusuf S, Arnold MJ, Sheridan P, Pogue J, Micks M, et al. Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. Homocysteine lowering with folic acid and B vitamins in vascular disease. New England Journal of Medicine 2006;354(15):1567-77.
9. Anonymous Homocysteine and progression of atherosclerosis. http://clinicaltrials.gov/ct2/show/NCT00005338 (accessed 1 May 2013). [: ClinicalTrials.gov Identifier: NCT00005338]
10. Musicant SE, Taylor LM Jr, Peters D, Schuff RA, Urankar R, Landry GJ, et al. Prospective evaluation of the relationship of between C-reactive protein, D-dimer and progression of peripheral arterial disease. Journal of Vascular Surgery 2006;43(4):772-80, discussion 780.
11. Nicoloff AD, Taylor JM Jr, Sexton GJ, Schuff RA, Edwards JMM, Yeager RA, et al. Homocysteine and Progression of Atherosclerosis Study Investigators. Relationship between site of initial symptoms and subsequent progression of disease in a prospective study of atherosclerosis progression in patients receiving long-term treatment for symptomatic peripheral arterial disease. Journal of Vascular Surgery 2002;35(1):38-46, discussion 46-7.
12. Taylor LM Jr, Moneta GL, Sexton GJ, Schuff RA, Porter JM. Prospective blinded study of the relationship between plasma homocysteine and progression of symptomatic peripheral arterial disease. Journal of Vascular Surgery 1999;29(1):8-19, discussion 19-21.
13. Adam DJ, Beard JD, Cleveland T, Bell J, Bradbury AW, Forbes JF, et al. Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial. Lancet 2005;366(9501):1925-34.
14. Anonymous Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials. Homocysteine Lowering Trialists' Collaboration. BMJ 1998;316(7135):894-8.
15. B-Vitamin Treatment Trialists' Collaboration. Homocysteine-lowering trials for prevention of cardiovascular events: a review of the design and power of the large randomized trials. American Heart Journal 2006;151(2):282-7.
16. Bainton D, Sweetnam P, Baker I, Elwood P. Peripheral vascular disease: consequence for survival and association with risk factors in the Speedwell prospective heart disease study. British Heart Journal 1994;72(2):128-32.
17. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995;274(13):1049-57.
18. Carmody BJ, Arora S, Avena R, Cosby K, Sidawy AN. Folic acid inhibits homocysteine-induced proliferation of human arterial smooth muscle cells. Journal of Vascular Surgery 1999;30(6):1121-8.
19. Cattaneo M. Hyperhomocysteinemia, atherosclerosis and thrombosis. Thrombosis and Haemostasis 1999;81(2):165-76.
20. Chao CL, Chien KL, Lee YT. Effect of short-term vitamin (folic acid, vitamins B6 and B12) administration on endothelial dysfunction induced by post-methionine load hyperhomocysteinemia. American Journal of Cardiology 1999;84(11):1359-61, A8.
21. Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. New England Journal of Medicine 1991;324(17):1149-55.
22. Clarke R, Smith AD, Jobst KA, Refsum H, Sutton L, Ueland PM. Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease. Archives of Neurology 1998;55(11):1449-55.
23. Collins R, Gray R, Godwin J, Peto R. Avoidance of large biases and large random errors in the assessment of moderate treatment effects: the need for systematic overviews. Statistics in Medicine 1987;6(3):245-54.
24. Coni N, Tennison B, Troup M. Prevalence of lower extremity arterial disease among elderly people in the community. British Journal of General Practice 1992;42(357):149-52.
25. Criqui MH, Denenberg JO, Langer RD, Fronek A. The epidemiology of peripheral arterial disease: importance of identifying the population at risk. Vascular Medicine 1997;2(3):221-6.
26. Currie IC, Wilson YG, Scott J, Day A, Stansbie D, Baird RN, et al. Homocysteine:an independant risk factor for the failure of vascular intervention. British Journal of Surgery 1996;83(9):1238-41.
27. den Heijer M, Rosendaal FR, Blom HJ, Gerrits WB, Bos GM. Hyperhomocysteinemia and venous thrombosis: a meta-analysis. Thrombosis and Haemostasis 1998;80(6):874-7.
28. Diehm C, Schuster A, Allenberg JR, Darius H, Haberl R, Lange S, et al. High prevalence of peripheral arterial disease and co-morbidity in 6880 primary care patients: cross-sectional study. Atherosclerosis 2004;172(1):95-105.
29. Dormandy JA, Murray GD. The fate of the claudicant -- a prospective study of 1969 claudicants. European Journal of Vascular Surgery 1991;5(2):131-3.
30. Franken DG, Boers GH, Blom HJ, Trijbels FJ, Kloppenborg PW. Treatment of mild hyperhomocysteinemia in vascular disease patients. Arteriosclerosis and Thrombosis 1994;14(3):465-70.
31. Hermans WR, Rensing BJ, Foley DP, Deckers JW, Rutsch W, Emanuelsson H, et al. Therapeutic dissection after successful coronary balloon angioplasty: no influence on restenosis or clinical outcome in 693 patients. The MERCATOR Study Group (Multicenter European Research Trial with Cilazapril after Angioplasty to prevent Transluminal Coronary Obstruction and Restenosis). Journal of the American College of Cardiology 1992;20(4):767-80.
32. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
33. Hooi JD, Kester ADM, Stoffers HE, Overdijk MM, van Ree JW, Knottnerus JA. Incidence of and risk factors for asymptomatic peripheral arterial occlusive disease: a longitudinal study. American Journal of Epidemiology 2001;153(7):666-72.
34. Inglis SC, Hermis A, Shehab S, Newton PJ, Lal S, Davidson PM. Peripheral arterial disease and chronic heart failure: a dangerous mix. Heart Failure Reviews 2013;18(4):457-64.
35. Irvine C, Wilson YG, Currie IC, McGrath C, Scott J, Day A, et al. Hyperhomocysteinaemia is a risk factor for vein graft stenosis. European Journal of Vascular and Endovascular Surgery 1996;12(3):304-9.
36. Iwama Y, Mokuno H, Yokoi H, Daida H, Yamaguchi H, Hosoda Y. [Elevated levels of plasma homocysteine related to saphenous vein graft disease after coronary artery bypass graft surgery]. Journal of Cardiology 1998 Dec;32(6):357-62.
37. Khandanpour N, Willis G, Meyer FJ, Armon MP, Loke YK, Wright AJ, et al. Peripheral arterial disease and methylenetetrahydrofolate reductase (MTHFR) C677T mutations: A case-control study and meta-analysis. Journal of Vascular Surgery 2009;49(3):711-8.
38. Khandanpour N, Loke YK, Meyer FJ, Jennings B, Armon MP. Homocysteine and peripheral arterial disease: systematic review and meta-analysis. European Journal of Vascular and Endovascular Surgery 2009;38(3):316-22.
39. Leng GC, Lee AJ, Fowkes FG, Whiteman M, Dunbar J, Housley E, et al. Incidence, natural history and cardiovascular events in symptomatic and asymptomatic peripheral arterial disease in the general population. International Journal of Epidemiology 1996;25(6):1172-81.
40. Malinow MR. Plasma homocyst(e)ine: a risk factor for arterial occlusive diseases. Journal of Nutrition 1996;126(4 Suppl):1238S-43S.
41. Malinow MR, Duell PB, Hess DL, Anderson PH, Kruger WD, Phillipson BE, et al. Reduction of plasma homocyst(e)ine levels by breakfast cereal fortified with folic acid in patients with coronary heart disease. New England Journal of Medicine 1998;338(15):1009-15.
42. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. Journal of the National Cancer Institute 1959;22(4):719-48.
43. Marti-Carvajal AJ, Solà I, Lathyris D, Karakitsiou DE, Simancas-Racines D. Homocysteine-lowering interventions for preventing cardiovascular events. Cochrane Database of Systematic Reviews 2013, Issue 1. [DOI: 10.1002/14651858.CD006612.pub3]
44. McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. American Journal of Pathology 1969;56(1):111-28.
45. McCully KS. Homocysteine and vascular disease. Nature Medicine 1996;2(4):386-9.
46. Mei W, Rong Y, Jinming L, Yongjun L, Hui Z. Effect of homocysteine interventions on the risk of cardiocerebrovascular events: a meta-analysis of randomised controlled trials. International Journal of Clinincal Practice 2010;64(2):208-15.
47. Meijer WT, Hoes AW, Rutgers D, Bots ML, Hofman A, Grobbee DE. Peripheral arterial disease in the elderly: The Rotterdam Study. Arteriosclerosis, Thrombosis, and Vascular Biology 1998;18(2):185-92.
48. Mireskandari M, Schachter M, Timms IGO, Sever P, Wolfe JHN. Plasma homocysteine is an independent risk factor for vein graft stenosis. British Journal of Surgery 1998;85 Suppl(Supp 1):27.
49. National Institute for Health and Clinical Excellence. Lower limb peripheral arterial disease: diagnosis and management. http://guidance.nice.org.uk/CG147/NICEGuidance/pdf/English August 2012 (accessed 4 July 2013).
50. Pell JP, Whyman MR, Fowkes FG, Gillespie I, Ruckley CV. Trends in vascular surgery since the introduction of percutaneous transluminal angioplasty. British Journal of Surgery 1994;81(6):832-5.
51. Refsum H, Ueland PM, Nygard O, Vollset SE. Homocysteine and cardiovascular disease. Annual Review of Medicine 1998;49:31-62.
52. Sakura N, Ono H, Nomura S, Ueda H, Fujita N. Betaine dose and treatment intervals in therapy for homocystinuria due to 5, 10-methylenetetrahydrofolate reductase deficiency. Journal of Inherited Metabolic Disease 1998;21(1):84-5.
53. Shammas NW. Epidemiology, classification, and modifiable risk factors of peripheral arterial disease. Vascular Health and Risk Management 2007;3(2):229-34.
54. Southern FN, Cruz N, Fink LM, Cooney CA, Barone GW, Eidt JF, et al. Hyperhomocysteinemia increases intimal hyperplasia in a rat carotid endarterectomy model. Journal of Vascular Surgery 1998;28(5):909-18.
55. Spark JI, Laws P, Fitridge R. The incidence of hyperhomocysteinaemia in vascular patients. European Journal of Vascular and Endovascular Surgery 2003;26(5):558-61.
56. Stoffers HE, Rinkens PE, Kester AD, Kaiser V, Knottnerus JA. The prevalence of asymptomatic and unrecognized peripheral arterial occlusive disease. International Journal of Epidemiology 1996;25(2):282-90.
57. Stoyioglou A, Jaff MR. Medical treatment of peripheral arterial disease: a comprehensive review. Journal of Vascular and Interventional Radiology 2004;15(11):1197-207.
58. Taylor LM Jr, Moneta GL, Sexton GJ, Schuff RA, Porter JM. Prospective blinded study of the relationship between plasma homocysteine and progression of symptomatic peripheral arterial disease. Journal of Vascular Surgery 1999;29(1):8-19, discussion 19-21.
59. Thompson MM, Budd JS, Eady SL, Underwood MJ, James RFL, Bell PRF. The effect of transluminal endothelial seeding on myointimal hyperplasia following angioplasty. European Journal of Vascular Surgery 1994;8(4):423-34.
60. Tierney S, Fennessy F, Hayes DB. ABC of arterial and vascular disease. Secondary prevention of peripheral vascular disease. BMJ 2000;320(7244):1262-5.
61. Verin V, Popowski Y, Urban P, Belenger J, Redard M, Costa M, et al. Intra-arterial beta irradiation prevents neointimal hyperplasia in a hypercholesterolemic rabbit restenosis model. Circulation 1995;92(8):2284-90.
62. Vermeulen EG, Stehouwer CD, Twisk JW, van der Berg M, De Jong SC, Mackaay AJ, et al. Effect of homocysteine-lowering treatment with folic acid plus vitamin B6 on progression of subclinical atherosclerosis: a randomised, placebo-controlled trial. Lancet 2000;355(9203):517-22.
63. Voller H. Peripheral arterial disease (PAD): secondary prevention. Deutsche Medizinische Wochenschrift 2002;127(37):1870-2.
64. White CJ, Gray WA. Endovascular therapies for peripheral arterial disease: an evidence-based review. Circulation 2007;116(19):2203-15.
65. Wilcken DE, Wilcken B, Dudman NP, Tyrrell PA. Homocystinuria - the effects of betaine in the treatment of patients not responsive to pyridoxine. New England Journal of Medicine 1983;309(8):448-53.
66. Wilcken DE, Dudman NP, Tyrrell PA. Homocystinuria due to cystathionine beta-synthase deficiency--the effects of betaine treatment in pyridoxine-responsive patients. Metabolism 1985;34(12):1115-21.
67. Woo KS, Chook P, Lolin YI, Sanderson JE, Metreweli C, Celermajer DS. Folic acid improves arterial endothelial function in adults with hyperhomocystinemia. Journal of the American College of Cardiology 1999;34(7):2002-6.
68. Yla-Herttuala S, Martin JF. Cardiovascular gene therapy. Lancet 2000;355(9199):213-22.
69. Hansrani M, Stansby GP. Homocysteine lowering interventions for peripheral arterial disease and bypass grafts. Cochrane Database of Systematic Reviews 2002, Issue 3. [DOI: 10.1002/14651858.CD003285]